A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIV

HIV viral reservoirs represent the major barrier to curing AIDS, and effectively reducing viral reservoirs in people living with HIV through different strategies has become a research priority in the HIV field.
Ipilimumab-tovorafenib monoclonal antibody injection (Aituo combination antibody, QL1706) contains two engineered monoclonal antibodies targeting PD-1 and CTLA-4. Chidamide is the first independently developed histone deacetylase inhibitor in China. This study aims to evaluate the safety and efficacy of Aituo combination antibody combined with chidamide in people living with HIV.
This study adopts a modified "1+3+3" dose-escalation design. Initially, one participant will be enrolled at dose level 1 (DL1) for safety observation. If the treatment is well tolerated, the study will proceed to a standard 3+3 design, with sequential dose escalation to DL2 and DL3.
Three dose levels are planned: DL1, the starting dose, consists of ipilimumab-tovorafenib monoclonal antibody injection at 0.3 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks. DL2 consists of ipilimumab-tovorafenib monoclonal antibody injection at 1 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks. DL3 consists of ipilimumab-tovorafenib monoclonal antibody injection at 2 mg/kg once every 4 weeks ± 1 day for a total of three doses, in combination with chidamide 10 mg orally twice weekly for 12 weeks.
During dose escalation, progression to the next dose level or discontinuation of escalation will be determined according to the occurrence of dose-limiting toxicities (DLTs). The DLT observation window is 28 days after the first dose. Participants evaluable for DLT are those who complete the observation window or experience a DLT. After completion of dose escalation, the maximum tolerated dose (MTD) will be determined based on safety and tolerability. If the MTD is not reached, DL3 will be selected as the dose for subsequent study.
After determination of the MTD or the subsequent study dose, an additional 11 participants will be enrolled at that dose level to further evaluate safety, tolerability, and preliminary efficacy. The maximum total sample size of the study will be 29 participants.

Start Date01 Jun 2026

Sponsor / Collaborator

The First Affiliated Hospital, Zhejiang University Sch of Med

NCT05890963

/ Active, not recruitingPhase 1IIT

Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis

This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in combination. The study will be conducted as a single center study at National Institute for Medical Research-Mbeya Medical Research Center (NIMR-MMRC) in Mbeya, Tanzania.
20 PLWH will be sequentially enrolled into one of 5 arms, each arm comprised of 4 participants. Sequential enrollment will occur in the following order:
* Arm 1 will receive standard daily oral ART.
* Arm 2 will receive a single dose of 10E8.4/iMab 600mg intravenous injection (IV).
* Arm 3 will receive a single dose of 10E8.4/iMab 600mg intramuscular injection (IM).
* Arm 4 will receive a single dose of 10E8.4/iMab 1800mg IV.
* Arm 5 will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV and VRC07-523LS 1200mg IV.

Start Date28 Nov 2023

Sponsor / Collaborator

Columbia University

[+2]

NCT05495204

/ CompletedNot Applicable

External Comparison of Effectiveness of Ibalizumab in Clinical Trials vs. Other HTE Regimens in OPERA

Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.

Start Date05 Aug 2022

Sponsor / Collaborator

Epividian, Inc.

[+1]

100 Clinical Results associated with Ibalizumab-UIYK

100 Translational Medicine associated with Ibalizumab-UIYK

100 Patents (Medical) associated with Ibalizumab-UIYK

Literatures (Medical) associated with Ibalizumab-UIYK

01 Apr 2026·JOURNAL OF MEDICAL VIROLOGY

HIV‐1 Non Group‐M Phenotypic Susceptibility to Ibalizumab

Article

Author: Jullien, Henri ; Poisson, Lucie ; Plantier, Jean‐Christophe ; Alessandri‐Gradt, Elodie ; Lermechain, Fanny ; Hingrat, Quentin Le ; Tombette, Fabienne

ABSTRACT:

The study assessed the phenotypic susceptibility of non group‐M human immunodeficiency virus type 1 (HIV‐1/non‐M) clinical isolates to ibalizumab, the first‐in‐class long‐acting CD4‐directed post‐attachment inhibitor. Thirty isolates were tested: 1 HIV‐1/M (reference strain BRU.HXB2), 2 HIV‐1/N, 26 HIV‐1/O and 1 HIV‐1/P. A phenotypic in vitro assay was performed by pre‐incubating peripheral blood mononuclear cells with ibalizumab, (1–10 000 ng/mL), then infected and incubated before quantifying viral load with RT‐PCR. IC 50 , maximum percent inhibition (MPI), and fold change (FC) were calculated. Potential N ‐glycosylation sites (PNGS) in the V5 loop, V2 loop length and the side chain at position 375 were investigated. Ibalizumab inhibited 22 HIV‐1/O and 1 HIV‐1/N strains, with a median IC 50 of 0.0413 (range: 6.19E10 −11 ; 16.8) ng/mL and a median MPI of 96.9 (range: 68.4; 99.3)%. The HIV‐1/P strain displayed potential resistance (IC 50 > 10 000 ng/mL; MPI < 25%). Interpretable results were not obtained for 4 HIV‐1/O and 1 HIV‐1/N strains under standardization criteria. PNGS numbers in the V5 loop ranged from 0 to 4 in tested isolates. Ibalizumab showed in vitro activity against all validated HIV‐1/O and HIV‐1/N isolates, whereas the HIV‐1/P strain exhibited potential natural resistance. No relationship was observed between PNGS number and susceptibility.

17 Mar 2026·CLINICAL INFECTIOUS DISEASES

Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series

Article

Author: Finkel, Diana ; Achhra, Amit ; Rolle, Charlotte ; Lucasti, Christopher ; McClendon, Tammie ; Martorell, Claudia ; Harbison, Christina ; Slim, Jihad

Abstract:

Background:

Some individuals with human immunodeficiency virus (HIV-1) have acquired multidrug-resistant (MDR) strains of HIV and/or are nonadherent to antiretroviral (ARV) medication. Injectable ARVs can provide salvage therapy for those with limited therapeutic options and may be preferred by some people with HIV (PWH). Real-world evidence may contribute to a more comprehensive understanding of the barriers to adherence and the utility of injectable ARVs in PWH. Currently, there is a lack of data on combined use of injectable ibalizumab (IBA) and lenacapavir (LEN) with optimized background regimen (OBR).

Methods:

A retrospective observational study examined medical charts from people with MDR HIV across 8 facilities in the United States. All PWH used a combination of both IBA + LEN ± OBR for at least 6 months. Viral loads and CD4+ counts were collected.

Results:

A total of 21 PWH were included. Four-class resistance at baseline was reported in 38.1% of PWH. Within 12 to 24 weeks of combined IBA + LEN treatment, a median reduction of −2710 copies/mL HIV RNA was observed. Median increase to CD4+ count was 67.5 cells/mm3 within 4 to 44 weeks of treatment initiation. Few intolerances required changes to treatment. Therapy with IBA + LEN continued for an average of 30 months and 20 months, respectively.

Conclusions:

In this small group of individuals with MDR HIV who were heavily treatment-experienced and/or faced adherence challenges, the use of IBA + LEN ± OBR was well tolerated and led to clinically significant reductions in viral loads and improvements in CD4+ counts.

01 Sep 2025·JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Ibalizumab Plus an Optimized Background Regimen in Treatment-Experienced People Living With Multidrug-Resistant HIV-1: A Phase 3, Multicenter, Expanded Access Study

Article

Author: Cash, Brandon R ; Kuo, Kuei-Ling ; Anstett, Kaitlin ; Berhe, Mezgebe ; Mills, Anthony ; Emu, Brinda ; Kumar, Princy N

Background::

People living with multidrug-resistant (MDR) HIV-1 have limited treatment options and poor clinical outcomes. For effective suppression of viral replication, regimens with distinct mechanisms of action and nonoverlapping patterns of resistance are needed.

Setting::

Studies of postattachment inhibitor ibalizumab plus optimized background regimen are needed to evaluate efficacy and safety of long-term use in people living with MDR HIV-1, potentially providing more treatment options.

Methods::

TMB-311 was a multicenter, open-label, expanded access phase 3 study that provided a compassionate bridge to commercial availability of ibalizumab for participants with and without prior exposure to drug.

Results::

In participants with prior exposure to ibalizumab, 23/39 (59%) had viral load (VL) <50 RNA copies/mL at study initiation and 27/35 (77%) had VL <50 copies/mL at week 24. In ibalizumab-naive participants receiving compassionate access, 0/38 (0%) had VL <50 copies/mL at study initiation compared with 11/24 (46%) at week 24. The mean CD4+ T-cell counts increased from baseline to week 24 across both participant groups. Rates of serious treatment-emergent adverse events up to week 120 were low. Discontinuations due to treatment-emergent adverse events were 0% in the participants with prior ibalizumab exposure and 8% in those who were ibalizumab-naive.

Conclusions::

Long-term ibalizumab treatment in combination with an optimized background regimen was considered safe and well-tolerated with no new safety signals identified in people living with MDR HIV-1. In addition, ibalizumab-naive participants experienced notable and early reductions in VL with sustained increases in CD4+ T-cell counts over 24 weeks.

Trial registration::

NCT02707861; registered on March 11, 2016, at Clinicaltrials.gov.

News (Medical) associated with Ibalizumab-UIYK

1 hours ago

·www.biospace.com

TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan

TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ("Orient EuroPharma"; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking the final step toward the commercial launch of Trogarzo in Taiwan. TaiMed stated that Trogarzo received a TFDA Approval Letter in June this year, formally approving its English and Chinese product names and therapeutic indication. Receipt of the TFDA Drug License Collection Notice signifies that the regulatory review process has been completed. Upon completion of the drug license issuance procedures and other commercialization preparations by Orient EuroPharma, Trogarzo will be officially launched in Taiwan, providing a new treatment option for patients living with multidrug-resistant HIV-1 infection. Trogarzo (ibalizumab) is the world's first and currently the only CD4-directed monoclonal antibody approved for the treatment of HIV. It is indicated, in combination with other antiretroviral agents, for the treatment of adults with multidrug-resistant HIV-1 infection who are heavily treatment-experienced and whose current antiretroviral regimen is failing. Trogarzo has received approval from the U.S. Food and Drug Administration (FDA) in both intravenous infusion (IV infusion) and intravenous push (IV Push) formulations. TaiMed is also actively pursuing regulatory approvals in additional countries and regions to further expand its global commercial footprint. TaiMed noted that it entered into an exclusive commercialization and distribution agreement with Orient EuroPharma for the Taiwan market in May 2024. Under the agreement, TaiMed is responsible for product supply, while Orient EuroPharma is responsible for regulatory registration, marketing, and commercialization. With its extensive experience in infectious disease and specialty pharmaceuticals, together with its well-established hospital network, Orient EuroPharma is well positioned to accelerate Trogarzo's market introduction in Taiwan and improve patient access to this innovative therapy. TaiMed further noted that although Trogarzo primarily addresses the relatively small salvage-treatment market for patients with multidrug-resistant HIV, the product offers a highly differentiated clinical pro has established a solid commercial foundation, continuing to contribute stable revenue to the Company. In the first quarter of this year, TaiMed successfully achieved profitability, marking a return to positive earnings and demonstrating the success of its Trogarzo commercialization strategy and global market expansion. Beyond Trogarzo, TaiMed is actively advancing the global clinical development of its next-generation long-acting dual broadly neutralizing antibody (bNAb) HIV therapy, TMB-365/380. The program completed Last Patient In (LPI) for its Phase 2b clinical trial in May 2026 and is expected to reach its interim data readout by the end of this year. Designed for once-every-two-month (Q2M) dosing, TMB-365/380 has the potential to become the world's first long-acting HIV antibody regimen that does not require viral susceptibility screening prior to treatment initiation, targeting the substantially larger first-line HIV maintenance therapy market. Peak annual global sales are estimated to reach US$3–4 billion. Subject to favorable clinical results and regulatory progress, the Company plans to pursue Breakthrough Therapy Designation (BTD) with the U.S. FDA, while advancing global licensing partnerships and commercialization opportunities. Dr. Jimmy Chang, CEO of TaiMed Biologics, commented: "Receiving the TFDA Drug License Collection Notice for Trogarzo represents another important validation of our years of research and development efforts and reflects the successful execution of our three core strategies—innovation, manufacturing, and commercialization. Looking ahead, we will continue expanding our global HIV portfolio by accelerating Trogarzo's international commercialization and advancing the global development of TMB-365/380. Our goal is to become a global leader in innovative HIV therapies while delivering sustainable long-term growth and value to our shareholders." About TaiMed Biologics Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV, and is advancing TMB-365/380, its lead clinical-stage long-acting maintenance therapy candidate for people living with HIV. TaiMed Biologics also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market since November 2015, currently part of the MSCI Small Cap Index. Forward-Looking Statements This press release contains forward-looking statements, including projections regarding clinical timelines, regulatory submissions, commercial potential, and partnering discussions for TMB-365/380. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions. TaiMed Biologics undertakes no obligation to update forward-looking statements except as required by applicable law. Contacts Investor Relations/Media Kenny Lin hlin@taimedbio.com

Drug ApprovalPhase 2NDABreakthrough Therapy

22 May 2026

·www.biospace.com

TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study

Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) today announced the completion of enrollment in its Phase 2b clinical study evaluating TMB-365/380, a novel investigational long-acting dual-antibody regimen for HIV maintenance therapy. The study reached Last Patient In (LPI) ahead of the planned schedule, marking an important operational milestone for the program. The Phase 2b study is designed to evaluate the efficacy and safety of TMB-365/380 as an every-two-month (Q2M), first-line HIV maintenance therapy for people living with HIV. With enrollment now complete, participants will continue scheduled follow-up, and TaiMed expects to report an interim analysis by year-end 2026. The Company believes the interim readout may help inform subsequent development and regulatory planning. Preliminary observations from ongoing follow-up show that viral suppression and relevant biomarkers following the first two doses are fully consistent with the Company’s expectations. Subject to continued positive outcomes, the Company plans to submit a Breakthrough Therapy Designation (BTD) application to the U.S. Food and Drug Administration (FDA). “Completing enrollment ahead of schedule reflects the strong execution of our clinical team and the commitment of our investigators, study sites, and participants,” said Dr. Jimmy Chang, Chief Executive Officer of TaiMed Biologics. “The accelerated enrollment highlights strong engagement from clinical sites and interest in Q2M long-acting treatment approaches. We believe TMB-365/380 has the potential to be the first long-acting bNAb combination to demonstrate high rates of viral suppression without the need for susceptibility screening, a distinction that could improve clinical access and patient convenience. We look forward to reporting interim data later this year.” TaiMed estimates peak annual global sales of TMB-365/380 at approximately USD $3–4 billion. TMB-365/380’s potential to offer a long-acting, infrequent-dosing treatment option without the need for susceptibility screening may support broad clinical use and differentiation within the evolving HIV treatment landscape. TaiMed Biologics is exploring potential strategic partnerships, including licensing and co-development opportunities, to support the global development and commercialization of TMB-365/380. About TaiMed Biologics Founded in 2007, TaiMed Biologics (4147.TWO) is a leading commercial-stage biotechnology company focused on developing innovative therapies for HIV treatment. The company successfully launched ibalizumab (Trogarzo®), the world's first and only FDA-approved monoclonal antibody for HIV, and is advancing TMB-365/380, its lead clinical-stage long-acting maintenance therapy candidate for people living with HIV. TaiMed Biologics also offers comprehensive contract development and manufacturing (CDMO) services and is publicly traded on the OTC Market since November 2015, currently part of the MSCI Small Cap Index. Forward-Looking Statements This press release contains forward-looking statements, including projections regarding clinical timelines, regulatory submissions, commercial potential, and partnering discussions for TMB-365/380. These statements involve known and unknown risks and uncertainties that could cause actual results to differ materially, including clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions. TaiMed Biologics undertakes no obligation to update forward-looking statements except as required by applicable law. Contacts Investor Relations Jonathan Ho jho@taimedbio.com Media Sofia Bermudez LifeSci Communications sbermudez@lifescicomms.com

Phase 2Drug ApprovalBreakthrough Therapy

11 Sep 2025

·www.globenewswire.com

Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors

– Dr. Chang led XOLAIR® from invention through FDA approval and commercialization, exceeding $5 billion in sales so far – Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Company”, “We” or “Us”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that Nancy T. Chang, former Tanox, Inc. CEO and proven biotechnology leader, has joined the Immix Biopharma Board of Directors concurrent with her investment as founding member of Goose Capital. At Tanox, Dr. Chang and her team invented and developed FDA-approved XOLAIR® (omalizumab) for severe asthma, TROGARZO® (ibalizumab-uiyk) for HIV, and EBGLYSS® (lebrikizumab-lbkz) for dermatitis, collectively generating drug sales exceeding 5 billion dollars so far. Tanox, Inc. was acquired by Genentech/Roche for $919 million. EBGLYSS® is commercialized by Eli Lilly and Co. About Immix Biopharma, Inc.Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that filters out non-specific activation. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NEXICART-2 primary endpoint was met at interim results presented at ASCO 2025. NXC-201 has been awarded Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA. Learn more at www.immixbio.com and www.BeProactiveInAL.com. Forward Looking StatementsThis press release contains forward-looking statements regarding Immix Biopharma, Inc., its results of operations, prospects, future business plans and operations and the matters discussed above, including, but not limited to, the potential benefits of our product candidate CAR-T NXC-201 and the timing and results related clinical trials. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Forward-looking statements also include, but are not limited to, our plans, objectives, expectations and intentions and other statements that contain words such as “expects”, “contemplates”, “anticipates”, “plans”, “intends”, “believes”, “estimates”, “potential”, and variations of such words or similar expressions that convey the uncertainty of future events or outcomes, or that do not relate to historical matters. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the further data from the ongoing Phase 1/2 clinical trials for CAR-T NXC-201 will not be favorably consistent with the data readouts to date, (ii) the risk that the Company may not be able to continue the NEXICART-2 multi-site U.S. Phase 1/2 clinical trial; (iii) the risk that the Company may not be able to advance to registration-enabling studies for CAR-T NXC-201 or other product candidates, (iv) that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; (v) that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (vi) the risk that the Company may not be able to obtain additional working capital with which to continue the clinical trials for CAR-T NXC-201, or advance to the initiation of registration-enabling studies, for such product candidates as and when needed and (vii) those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K filed with the SEC on March 25, 2025 and other periodic reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. ContactsMike MoyerLifeSci Advisorsmmoyer@lifesciadvisors.com Company Contactirteam@immixbio.com

Cell TherapyOrphan DrugDrug ApprovalImmunotherapyClinical Study

100 Deals associated with Ibalizumab-UIYK

External Link

KEGG	Wiki	ATC	Drug Bank
D09575	Ibalizumab-UIYK	J05AX23	DB12698

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	Theratechnologies, Inc.	06 Mar 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 3	United States	TaiMed Biologics, Inc.	01 Aug 2015
Acquired Immunodeficiency Syndrome	Phase 3	Taiwan Province	TaiMed Biologics, Inc.	01 Aug 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03913195 (CTgov)	Phase 3	HIV Infections	43	ibalizumab-uiyk (Core Group-HIV Uninfected)	gcmubrskwh = gxsepjojju gxahpsqkha (lxpvbgsyvh, frtctfrprc - dnbwazbfis) View more	-	20 Oct 2025
				ibalizumab-uiyk (Intramuscular Injection Group-HIV+)	zmptalbfoc = ldxcezoule beqsyylvtm (iippgolxkm, sqigovsjkg - bmywozrvzh) View more
NCT05388474 (PROMISE-US, Company_Website) Manual	Phase 4	HIV Infections	112	matched patients not receiving ibalizumab (Cohort 1)	fvqrgxkomp(jopyreehwp) = Among those with baseline viremia, 50% of Cohort 1 participants and 47% in Cohort 2 achieved undetectable viral load (≤50 RNA copies/mL) after six months of treatment (p=0.873). At 12 months, viral load was undetectable in 53% of Cohort 1 participants and in 42% of those in Cohort 2 (p=0.0.524). pzqqhcuvxp (rwbefuuvts ) View more	Positive	12 Mar 2025
				ibalizumab (Cohort 2)
Biospace Manual	Phase 2/3	HIV Infections	76	ibalizumab 800 mg	rxfhygvbam(askptrnmnj): 1.98 (95% CI, 1.02 - 3.69) View more	Positive	12 Jul 2023
				non-ibalizumab-containing regimens
NCT00089700 (Pubmed \| J Acquir Immune Defic Syndr)	Phase 2	HIV Infections	82	Ibalizumab 15 mg/kg q2wk	yfyqodjhyy(viwkfnkgaz) = No ibalizumab-related serious adverse events were reported rygbqppfud (uevxpdsfmh )	Positive	01 Apr 2021
				Ibalizumab 10 mg/kg weekly for 9 weeks, then q2wk
NCT02707861 (CTgov)	Phase 3	HIV Infections	79	Optimized Background Regimen+ibalizumab (Cohort 1)	bxqnnqonnh = jzwdxnhuon vuyuqjgvci (zzzkwoseay, ubliboqefb - pevazjkyvw) View more	-	11 Mar 2021
				Optimized Background Regimen+ibalizumab (Cohort 2)	bxqnnqonnh = ezikdyygup vuyuqjgvci (zzzkwoseay, ifvabnnrcc - nqlaqavvuv) View more
NCT02475629 (CTgov)	Phase 3	Acquired Immunodeficiency Syndrome \| HIV Infections	40	Optimized Background Regimen (OBR)+ibalizumab	aivqsscrot = fbjreunkxl voxsvfryju (jcvmekopba, hyqvejygjr - dsjseetkgs) View more	-	19 Mar 2020
NCT02475629 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 3	HIV Infections	40	Ibalizumab	wvupsamplh(ipdmrufkqm) = puakzrhnre jxzbqhemmz (wkwlpaxefg ) View more	Positive	16 Aug 2018
NCT00784147 (TMB-202, IAS2017)	Not Applicable	HIV Infections	113	Ibalizumab	pdhzkljbhr(rudwzucpfz) = xbqvoedbdl qytuwzafae (aslguyzmko )	-	01 Jan 2017
NCT00784147 (TMB-202, CTgov)	Phase 2	Acquired Immunodeficiency Syndrome \| HIV Infections	113	Ibalizumab (Ibalizumab 800 mg)	cxojrlvuju = famjikqjrv ijkxpaihgg (jzmbsbcvpy, phdnlouilx - jhaqyxmdns) View more	-	17 Apr 2014
				Ibalizumab (Ibalizumab 2000 mg)	cxojrlvuju = hrnrfqihhe ijkxpaihgg (jzmbsbcvpy, ydbmbqimrq - harkdqslzg) View more
IAS2006	Not Applicable	-	82	TNX-355 15mg/kg+OBR	gjdcutvsnw(ytqcoqzogx) = fmsxvlfoxs lfnsclpvio (mroxeieewu )	-	01 Jan 2006
				TNX-355 10mg/kg+OBR	gjdcutvsnw(ytqcoqzogx) = juvwsyefnm lfnsclpvio (mroxeieewu )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis